Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial

The combination of the campothecan-containing nanoparticle–drug conjugate, CRLX101 and bevacizumab is well tolerated, safe, and active in a heavily pretreated population of patients with metastatic renal cell carcinoma of clear and non-clear cell histology.

from Cancer via ola Kala on Inoreader http://ift.tt/25PYZz0
via IFTTT